Staidson, a biopharmaceutical company developing investigational products by targeting the complement system and Pivotal, a European-wide full-service CRO, headquartered in Madrid, have announced t...
Read moreVTX-803, co-desarrollado por el Cima Universidad de Navarra y Vivet Therapeutics, está indicado para el tratamiento de la colestasis intrahepática familiar progresiva de tipo 3
Read moreThe company announced the initiation a of a drug discovery program towards the identification of novel oral drugs specifically designed to treat infections caused by Corona viruses.
Read moreInvestigadores del Programa de Tumores Respiratorios del CIBERONC han demostrado el impacto del infiltrado inmune intratumoral en el pronóstico de pacientes con carcinoma de cabeza y cuello no relaci...
Read moreThe COVID-19 fund of the Carlos III Health Institute (ISCIII) awards a project to the Barcelona Supercomputing Center (BSC), lead by Víctor Guallar, in collaboration of Nostrum Biodiscovery ...
Read moreLa revista ‘The Lancet Microbe’ publica un estudio, liderado por IrsiCaixa, que describe el caso de un hombre portador del VIH cuyo virus es resistente a todos los fármacos antirretrovirales oral...
Read moreThe biopharmaceutical company Ability Pharmaceuticals SL announced today that the full description of the mechanism of action of ABTL0812 has been published in the prestigious Autophagy journal (impac...
Read moreA study led by researchers from the Institut de Neurociències (INc-UAB), in collaboration with the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), describes a new mechanism by which the an...
Read moreYsios Capital, a leading biotechnology venture capital firm in Spain, today announced its third fund, Ysios BioFund III, with a committed amount of € 155M and a final target size of € 200M.
Read moreEl artículo “Cancer Patients and Anxiety: A Gender Perspective” publicado en “International Journal of Environmental Research and Public Health” forma parte de un estudio que recibió el prim...
Read moreThe biotech company Oxolife, created to develop a new treatment to improve the female fertility rate, completed its first funding round by raising 5,000,000 euros in an investment led by Inveready Ass...
Read more